CJC-1295 with DAC vs Tesamorelin
Long-acting growth hormone releaser that works around the clock to boost your body's natural GH production with just one or two injections per week.
The only FDA-approved peptide specifically designed to melt away stubborn belly fat by telling your brain to release more growth hormone naturally—working with your body's own systems rather than replacing them [6].
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
CJC-1295 with DAC
2–2 mg
Tesamorelin
2–2 mg
Frequency
CJC-1295 with DAC
Twice weekly
Tesamorelin
Once daily
Administration
CJC-1295 with DAC
Subcutaneous injection
Tesamorelin
Subcutaneous injection
Cycle length
CJC-1295 with DAC
8-12 weeks
Tesamorelin
12+ weeks
Onset speed
CJC-1295 with DAC
Moderate (1-2 weeks)
Tesamorelin
Moderate (1-2 weeks)
Evidence level
CJC-1295 with DAC
Moderate human trials (Phase 1-2)
Tesamorelin
Strong human trials (Phase 3 or FDA approved)
Benefit ratings
GH Elevation
Convenience
Recovery Support
Visceral Fat Reduction
Metabolic Health
Natural GH Boost
Compound specifications
CJC-1295 with DAC
Molecular formula
C165H269N47O46
Molecular weight
3647.28 g/mol
Half-life
6-8 days
Bioavailability
~100% (subcutaneous)
CAS number
863288-34-0
Tesamorelin
Molecular formula
C221H366N72O67S
Molecular weight
5135.86 g/mol
Half-life
26-38 minutes
Bioavailability
~100% (subcutaneous injection)
CAS number
218949-48-5
Dosing compared
CJC-1295 with DAC
Subcutaneous
1 mg (1000 mcg)
Once weekly · 2-4 weeks
A starting dose used in practice. The DAC version is long-acting (about a 6-8 day half-life), so weekly dosing keeps growth hormone and IGF-1 raised. In the Phase 1 trial a single dose raised GH for 6+ days and IGF-1 for up to 11 days. [2]
2 mg (2000 mcg)
Once weekly (or split twice weekly) · 8-12 weeks
The common maintenance dose, roughly in line with the 30-60 mcg/kg weekly range studied in the Phase 1 trial. [1][2] In the ascending-dose trials, single injections raised mean GH 2- to 10-fold for six or more days and IGF-I 1.5- to 3-fold for 9-11 days; 30 and 60 µg/kg doses were the best tolerated [2].
2 mg per dose
Twice weekly · 8-12 weeks
A higher total weekly amount split into two doses, used by experienced users; near the top of the 30-60 mcg/kg weekly range from the clinical study. [2]
Tesamorelin
Subcutaneous
2 mg (1.4 mg with Egrifta SV/WR F8 formulation)
Once daily · 26 weeks, continued long-term for sustained effect
FDA-approved dose for HIV-associated lipodystrophy; full dose from day one with no titration [6]. Pivotal phase 3 trials used 2 mg daily [1].
Best suited for
CJC-1295 with DAC
Growth Hormone Optimization
CJC-1295 with DAC excels at providing a sustained, steady elevation of growth hormone levels. Unlike shorter-acting peptides that create brief spikes, the DAC modification keeps GH elevated for days, mimicking a more youthful hormone profile.
Muscle Building and Recovery
By increasing both GH and IGF-1 levels, this peptide supports protein synthesis and muscle repair. Users often notice improved recovery between workouts and better ability to build and maintain lean muscle mass.
Anti-Aging and Longevity
Growth hormone naturally declines with age, contributing to many signs of aging. CJC-1295 with DAC helps restore more youthful GH levels, potentially supporting better skin quality, energy levels, and overall vitality.
Body Composition Improvement
The combination of increased GH and IGF-1 promotes fat metabolism while preserving muscle tissue. Many users experience gradual fat loss, particularly in stubborn areas, while maintaining or building lean mass.
Convenient Weekly Dosing
Unlike peptides requiring daily or twice-daily injections, the extended half-life of CJC-1295 with DAC means just one or two injections per week provide continuous benefits. Ideal for those who want results without daily protocols.
Tesamorelin
People with Stubborn Visceral Fat
If you carry your weight around your midsection—the deep belly fat that wraps around your organs—tesamorelin is specifically designed for you. Unlike weight loss drugs, it targets visceral fat while preserving the normal subcutaneous fat that's healthy to have [5].
HIV Patients with Lipodystrophy
Tesamorelin is FDA-approved specifically for HIV-associated lipodystrophy—the abnormal fat accumulation in the belly that antiretroviral medications can cause [6]. It's the only treatment proven to help this condition, reducing both the physical and psychological burden [1][5].
Those Concerned About Metabolic Health
Visceral fat isn't just cosmetic—it's metabolically dangerous, linked to heart disease, diabetes, and inflammation [10][12]. By reducing visceral fat, tesamorelin also improves triglycerides, cholesterol ratios, and may help protect your liver from fatty liver disease [1][2][4].
Adults Wanting Natural GH Stimulation
Unlike synthetic growth hormone injections, tesamorelin works WITH your body's natural systems. It tells your pituitary to release more of YOUR OWN growth hormone, maintaining normal feedback loops and reducing the risks associated with supraphysiological GH levels [10].
Side effects
CJC-1295 with DAC
Common
- Injection site reactions
- Water retention
- Flushing
- Tingling sensation
Uncommon
- Headaches
- Fatigue or lethargy
- Joint discomfort
Serious
- Carpal tunnel symptoms
- Blood glucose elevation
Tesamorelin
Common
- Injection site reactions
- Joint pain (arthralgia)
- Muscle pain (myalgia)
- Peripheral edema
Uncommon
- Carpal tunnel symptoms
- Elevated blood glucose
Serious
- Severe allergic reaction
- Worsening diabetes
Safety & evidence
CJC-1295 with DAC
Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
CJC-1295 with DAC was evaluated in Phase 1-2 human clinical trials where it demonstrated a generally favorable safety profile. The most common adverse events were mild injection site reactions including temporary pain, swelling, and redness. No serious adverse events were reported in the published clinical studies. The compound was being developed for HIV-associated lipodystrophy before the program was discontinued.
Contraindications
- Active cancer or history of malignancy
- Pregnancy or breastfeeding
- Pituitary tumors or disorders
- Diabetic retinopathy
- Uncontrolled diabetes
Tesamorelin
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for other use
Safety overview
Tesamorelin has a strong safety profile backed by FDA approval and multiple large Phase 3 clinical trials involving over 800 patients [1][6]. The most common issues are injection site reactions and the typical side effects of elevated growth hormone (joint pain, fluid retention) [6]. Glucose metabolism should be monitored as some patients experience increased blood sugar [6]. Long-term cardiovascular safety data is still being collected, which is why the FDA recommends reassessing treatment if visceral fat doesn't reduce [6].
Contraindications
- Active malignancy [6] or history of cancer (pituitary tumors especially)
- Known hypersensitivity to tesamorelin or mannitol [6]
- Pregnancy [6]
- Disruption of the hypothalamic-pituitary axis from conditions like hypophysectomy or pituitary tumor surgery [6]
Which is right for you?
Choose CJC-1295 with DAC if...
- Boosting natural growth hormone production
- Building lean muscle mass
- Improving body composition
- Anti-aging and longevity
Choose Tesamorelin if...
- Reducing visceral abdominal fat
- Improving metabolic health markers
- Supporting natural growth hormone production
- Addressing HIV-associated lipodystrophy